Figures & data
Table 1 Demographics of COPD subjects
Figure 1 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on phagocytosis of beads or bacteria at 1 hour and 4 hours.
![Figure 1 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on phagocytosis of beads or bacteria at 1 hour and 4 hours.](/cms/asset/8423c95e-ebf8-4194-bb5e-96282e87fa81/dcop_a_169337_f0001_b.jpg)
Figure 2 Effects of 18 hours’ pretreatment with fluticasone propionate or budesonide on phagocytosis of beads or bacteria at 1 hour and 4 hours.
![Figure 2 Effects of 18 hours’ pretreatment with fluticasone propionate or budesonide on phagocytosis of beads or bacteria at 1 hour and 4 hours.](/cms/asset/8b2e8576-9976-42b1-afcb-305a8ca798e1/dcop_a_169337_f0002_b.jpg)
Figure 3 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on release of CXCL8, IL6, and TNFα induced by phagocytosis of beads or bacteria at 4 hours.
Notes: (A–C) Monocyte-derived macrophages from COPD patients (n=12) were left not treated (NT), or pretreated for 1 hour with drug vehicle (V) prior to incubation with fluorescently labeled beads, Haemophilus influenzae (HI), or Streptococcus pneumoniae (SP) bacteria for 4 hours. Supernatants were analyzed by ELISA for CXCL8 (A), IL6 (B), and TNFα (C) release. Data are mean ± SEM; **P<0.01, ***P<0.001 between no treated (NT) and treatment. (D–L) Monocyte-derived macrophages from COPD patients (n=12) were pretreated for 1 hour with fluticasone propionate (○) or budesonide (●) at indicated concentrations or drug vehicle (V) prior to incubation with fluorescently labeled beads or bacteria for 4 hours. Supernatants were analyzed by ELISA for CXCL8, IL6, and TNFα release. Data are percentage responses compared to vehicle control, expressed as mean ± SEM; *P<0.05, **P<0.01 between drugs and vehicle (V).
![Figure 3 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on release of CXCL8, IL6, and TNFα induced by phagocytosis of beads or bacteria at 4 hours.Notes: (A–C) Monocyte-derived macrophages from COPD patients (n=12) were left not treated (NT), or pretreated for 1 hour with drug vehicle (V) prior to incubation with fluorescently labeled beads, Haemophilus influenzae (HI), or Streptococcus pneumoniae (SP) bacteria for 4 hours. Supernatants were analyzed by ELISA for CXCL8 (A), IL6 (B), and TNFα (C) release. Data are mean ± SEM; **P<0.01, ***P<0.001 between no treated (NT) and treatment. (D–L) Monocyte-derived macrophages from COPD patients (n=12) were pretreated for 1 hour with fluticasone propionate (○) or budesonide (●) at indicated concentrations or drug vehicle (V) prior to incubation with fluorescently labeled beads or bacteria for 4 hours. Supernatants were analyzed by ELISA for CXCL8, IL6, and TNFα release. Data are percentage responses compared to vehicle control, expressed as mean ± SEM; *P<0.05, **P<0.01 between drugs and vehicle (V).](/cms/asset/2cecb246-893b-4ec3-9b33-adebe0cef10f/dcop_a_169337_f0003_b.jpg)
Figure 4 Effects of 18 hour's pretreatment with fluticasone propionate or budesonide on release of CXCL8, IL6, and TNFα induced by phagocytosis of beads or bacteria at 4 hours.
![Figure 4 Effects of 18 hour's pretreatment with fluticasone propionate or budesonide on release of CXCL8, IL6, and TNFα induced by phagocytosis of beads or bacteria at 4 hours.](/cms/asset/244f0c64-1c0a-4b12-8a8b-8d9e92113612/dcop_a_169337_f0004_b.jpg)
Table 2 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on scavenger-receptor expression
Figure 5 Effects of fluticasone propionate or budesonide on intracellular killing of Haemophilus influenzae or Streptococcus pneumoniae by MDMs from COPD patients.
Abbreviation: MDMs, monocyte-derived macrophages.
![Figure 5 Effects of fluticasone propionate or budesonide on intracellular killing of Haemophilus influenzae or Streptococcus pneumoniae by MDMs from COPD patients.](/cms/asset/33b8e016-9213-41aa-b68a-bfe5945d58de/dcop_a_169337_f0005_b.jpg)
Figure S1 Effects of fluticasone propionate or budesonide on viability of MDMs after phagocytosis.
Notes: MDMs from COPD patients (n=20–24) were untreated (UC [untreated control]), or pretreated for 1 hour (A–F) or 18 hours (G–L) with fluticasone propionate (○), budesonide (●), or drug vehicle (V) prior to incubation with fluorescently labeled beads or bacteria for 1 hour or 4 hours. Cell viability was measured by MTT assay. Data presented as percentage viability compared to UC and shown as mean ± SEM; *P<0.05 between UC and drug.
Abbreviation: MDMs, monocyte-derived macrophages.
![Figure S1 Effects of fluticasone propionate or budesonide on viability of MDMs after phagocytosis.Notes: MDMs from COPD patients (n=20–24) were untreated (UC [untreated control]), or pretreated for 1 hour (A–F) or 18 hours (G–L) with fluticasone propionate (○), budesonide (●), or drug vehicle (V) prior to incubation with fluorescently labeled beads or bacteria for 1 hour or 4 hours. Cell viability was measured by MTT assay. Data presented as percentage viability compared to UC and shown as mean ± SEM; *P<0.05 between UC and drug.Abbreviation: MDMs, monocyte-derived macrophages.](/cms/asset/0cd7e3ed-26b0-45ba-92ba-cad83e9d6b64/dcop_a_169337_sf0001_b.jpg)
Figure S2 Flow cytometry gating strategy.
Notes: (A–H) Monocyte-derived macrophages were gated by the forward-scatter (FSc) vs side-scatter (SSc) population. Negative expression was gated on untreated population (red) or secondary antibody (MARCO), and a shift to the right indicates positive expression of receptors. Graphs show untreated cells (blue), H. influenzae-positive cells (light green), and cells treated with fluticasone propionate (orange), budesonide (dark green), and vehicle control (pink).
![Figure S2 Flow cytometry gating strategy.Notes: (A–H) Monocyte-derived macrophages were gated by the forward-scatter (FSc) vs side-scatter (SSc) population. Negative expression was gated on untreated population (red) or secondary antibody (MARCO), and a shift to the right indicates positive expression of receptors. Graphs show untreated cells (blue), H. influenzae-positive cells (light green), and cells treated with fluticasone propionate (orange), budesonide (dark green), and vehicle control (pink).](/cms/asset/74bff3d0-8298-4d87-86f3-9c2e31423fa7/dcop_a_169337_sf0002_c.jpg)
Figure S3 Effects of fluticasone propionate or budesonide on percent phagocytosis of Haemophilus influenzae and Streptococcus pneumoniae by COPD neutrophils.
Notes: Neutrophils from COPD patients were pretreated with fluticasone propionate (○) or budesonide (●) at indicated concentrations or drug vehicle (V) for 1 hour and subsequently incubated with H. influenzae (A–D) or S. pneumoniae (E–H) for 5, 10, 15, or 60 minutes, cells washed, fixed in 4% paraformaldehyde, and fluorescence measured by flow cytometry. Graphs show percentage of neutrophils that phagocytosed bacteria. Data shown as mean ± SEM with no statistical differences observed; n=7.
![Figure S3 Effects of fluticasone propionate or budesonide on percent phagocytosis of Haemophilus influenzae and Streptococcus pneumoniae by COPD neutrophils.Notes: Neutrophils from COPD patients were pretreated with fluticasone propionate (○) or budesonide (●) at indicated concentrations or drug vehicle (V) for 1 hour and subsequently incubated with H. influenzae (A–D) or S. pneumoniae (E–H) for 5, 10, 15, or 60 minutes, cells washed, fixed in 4% paraformaldehyde, and fluorescence measured by flow cytometry. Graphs show percentage of neutrophils that phagocytosed bacteria. Data shown as mean ± SEM with no statistical differences observed; n=7.](/cms/asset/d54701b8-d286-40c5-83da-dafe66b4527e/dcop_a_169337_sf0003_b.jpg)
Figure S4 Effects of fluticasone propionate or budesonide on amount of Haemophilus influenzae and Streptococcus pneumoniae phagocytosed by COPD neutrophils.
Notes: Neutrophils from COPD patients were pretreated with fluticasone propionate (○) or budesonide (●) at indicated concentrations or drug vehicle (V) for 1 hour and subsequently incubated with H. influenzae (A–D) or S. pneumoniae (E–H) for 5, 10, 15, or 60 minutes, cells washed, fixed in 4% paraformaldehyde, and fluorescence measured by flow cytometry. Graphs show the amount of phagocytosed bacteria expressed as median fluorescence intensity (MFI). Data shown as mean ± SEM with no statistical differences observed; n=7.
![Figure S4 Effects of fluticasone propionate or budesonide on amount of Haemophilus influenzae and Streptococcus pneumoniae phagocytosed by COPD neutrophils.Notes: Neutrophils from COPD patients were pretreated with fluticasone propionate (○) or budesonide (●) at indicated concentrations or drug vehicle (V) for 1 hour and subsequently incubated with H. influenzae (A–D) or S. pneumoniae (E–H) for 5, 10, 15, or 60 minutes, cells washed, fixed in 4% paraformaldehyde, and fluorescence measured by flow cytometry. Graphs show the amount of phagocytosed bacteria expressed as median fluorescence intensity (MFI). Data shown as mean ± SEM with no statistical differences observed; n=7.](/cms/asset/28232f78-a2b7-4e3c-a81d-e7177c7e18e7/dcop_a_169337_sf0004_b.jpg)
Table S1 Effects of 18 hours’ pretreatment with fluticasone propionate (FP) or budesonide (Bud) on scavenger-receptor expression